Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales.
Kiran SamraAmy MacdougallGeorgia PeakmanArabella BouziguesMartina BocchettaDavid M CashCaroline V GreavesRhian S ConveryJohn Cornelis van SwietenLize C JiskootHarro SeelaarFermin MorenoRaquel Sánchez-ValleRobert LaforceCaroline GraffMario MasellisMaria Carmela TartagliaJames Benedict RoweBarbara BorroniElizabeth C FingerMatthis SynofzikDaniela GalimbertiRik VandenbergheAlexandre de MendoncaChristopher R ButlerAlexander GerhardSimon DucharmeIsabelle Le BerPietro TiraboschiIsabel SantanaFlorence PasquierJohannes LevinMarkus OttoSandro SorbiJonathan Daniel RohrerLucy L Russellnull nullnull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
Neuropsychiatric symptoms occur in mutation carriers at all disease stages across all three genetic groups. However, only psychosis features provided additional staging benefit to the CDR plus NACC FTLD. Inclusion of these features brings us closer to optimising the rating scale for use in trials.